Loss of thrombospondin transcriptional activity in nickel-transformed cells.
about
Molecular mechanisms in nickel carcinogenesis: modeling Ni(II) binding site in histone H4.Ascorbate depletion: a critical step in nickel carcinogenesis?Inhibition of core histones acetylation by carcinogenic nickel(II)Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma.In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects.Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens.SPARC and thrombospondin genes are repressed by the c-jun oncogene in rat embryo fibroblasts.Invoking the power of thrombospondins: regulation of thrombospondins expressionActivating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion.Essential role of PI-3K, ERKs and calcium signal pathways in nickel-induced VEGF expression.Human cytomegalovirus infection decreases expression of thrombospondin-1 independent of the tumor suppressor protein p53.The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun.Nickel carcinogenesis, mutation, epigenetics, or selection.Promoter regulatory elements and DNase I-hypersensitive sites involved in serglycin proteoglycan gene expression in human erythroleukemia, CHRF 288-11, and HL-60 cells.Interaction of Cu(II) and Ni(II) with the 63-93 fragment of histone H2B.Interactions of Ni(II) and Cu(II) ions with the hydrolysis products of the C-terminal -ESHH- motif of histone H2A model peptides. Association of the stability of the complexes formed with the cleavage of the -E-S- bond.Interaction of histone H2B (fragment 63-93) with Ni(ii). An NMR study.Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene.Methylation and silencing of the Thrombospondin-1 promoter in human cancer.A pharmacokinetic model of the intracellular dosimetry of inhaled nickel.
P2860
Q24812388-746B122A-81B2-49CA-B211-DF3DB7D70979Q24812869-56781575-02C3-400B-A529-70311F1DAEBDQ28281427-0182C534-1D1C-41CD-A84D-0212008DCDF2Q34443645-295F9DE5-D26E-416E-9CE3-DE363D76C55DQ35079190-A9B049A9-43F8-4A1B-AA50-1AC1467E6DACQ36550875-A77A9F7A-9F0C-46F1-81A3-85D96FBF1194Q36729700-38C48D50-43DD-419C-9372-69CD36643D59Q38192305-FA099425-7536-423B-9413-2B32DFA1C78BQ40149614-5D32E479-2FF8-4A42-89FD-625694FF2917Q40352133-11EFE76C-9350-423F-8F7A-E99D6DF06F5BQ40943878-62E633E2-05B9-479E-9C9D-DC52F905FBEAQ40952388-CD3148FF-3E2F-482A-AF5A-3E15CEAF2A05Q43198047-D9C962C7-9074-46D5-A0A1-245220E73382Q43595440-11CC7E0B-BF62-45CB-B618-BAB3328A2A7FQ43848895-31870DDA-982F-4140-9BDA-EF5CCDCE30FEQ45169207-48114446-022C-4A28-B64F-9EBC59988F01Q46101464-8775B7E6-538E-4E38-B9F7-839058F73157Q47628529-57AF57E9-89D9-4B91-9C7C-59752A21D6A2Q48192580-4BE2ABBA-8DC2-4B96-900C-74AF74773049Q53334206-50F7BF64-B388-405C-97C9-9E7478F12415
P2860
Loss of thrombospondin transcriptional activity in nickel-transformed cells.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Loss of thrombospondin transcriptional activity in nickel-transformed cells.
@ast
Loss of thrombospondin transcriptional activity in nickel-transformed cells.
@en
type
label
Loss of thrombospondin transcriptional activity in nickel-transformed cells.
@ast
Loss of thrombospondin transcriptional activity in nickel-transformed cells.
@en
prefLabel
Loss of thrombospondin transcriptional activity in nickel-transformed cells.
@ast
Loss of thrombospondin transcriptional activity in nickel-transformed cells.
@en
P2093
P2860
P356
P1476
Loss of thrombospondin transcriptional activity in nickel-transformed cells.
@en
P2093
P2860
P304
P356
10.1128/MCB.14.1.851
P407
P577
1994-01-01T00:00:00Z